2026-08-29T10:38:19Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/186812024-02-27T15:08:43Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16982

00925njm 22002777a 4500 dc Mena-Vázquez, Natalia author Rojas-Gimenez, Marta author Fuego-Varela, Clara author García-Studer, Aimara author Perez-Gómez, Nair author Romero-Barco, Carmen María author Godoy-Navarrete, Francisco Javier author Manrique-Arija, Sara author Gandía-Martínez, Myriam author Calvo-Gutiérrez, Jerusalem author Morales-Garrido, Pilar author Mouriño-Rodriguez, Coral author Castro-Pérez, Patricia author Añón-Oñate, Isabel author Espildora, Francisco author Aguilar-Hurtado, María Carmen author Hidalgo Conde, Ana author Arnedo Díez de Los Ríos, Rocío author Cabrera César, Eva author Redondo-Rodriguez, Rocío author Velloso-Feijoo, María Luisa author Fernández-Nebro, Antonio author 2022-06-22 To prospectively evaluate the safety and efficacy profile of abatacept in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). We performed a prospective observational multicenter study of a cohort of patients with RA-ILD treated with abatacept between 2015 and 2021. Patients were evaluated using high-resolution computed tomography and pulmonary function tests at initiation, 12 months, and the end of follow-up. The effectiveness of abatacept was evaluated based on whether ILD improved, stabilized, progressed, or was fatal. We also evaluated factors such as infection, hospitalization, and inflammatory activity using the 28-joint Disease Activity Score with the erythrocyte sedimentation rate (DAS28-ESR). Cox regression analysis was performed to identify factors associated with progression of lung disease. The study population comprised 57 patients with RA-ILD treated with abatacept for a median (IQR) of 27.3 (12.2-42.8) months. Lung disease had progressed before starting abatacept in 45.6% of patients. At the end of follow-up, lung disease had improved or stabilized in 41 patients (71.9%) and worsened in 13 (22.8%); 3 patients (5.3%) died. No significant decreases were observed in forced vital capacity (FVC) or in the diffusing capacity of the lung for carbon monoxide (DLCO).The factors associated with progression of RA-ILD were baseline DAS28-ESR (OR [95% CI], 2.52 [1.03-3.12]; p = 0.041), FVC (OR [95% CI], 0.82 [0.70-0.96]; p = 0.019), and DLCO (OR [95% CI], 0.83 [0.72-0.96]; p = 0.018). Only 10.5% of patients experienced severe adverse effects. Pulmonary function and joint inflammation stabilized in 71% of patients with RA-ILD treated with abatacept. Abatacept had a favorable safety profile. 10.3390/biomedicines10071480 2227-9059 Biomedicines http://hdl.handle.net/10668/20838 35884786 http://hdl.handle.net/20.500.12105/18681 abatacept biologics interstitial lung disease rheumatoid arthritis Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease.